A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

NCT01941095 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Azathioprine
DRUG: Chloroquine
DRUG: Hydroxychloroquine
DRUG: Leflunomide
DRUG: Methotrexate
DRUG: Sulfasalazine
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche